Impact of biologics on lung hyperinflation in patients with severe asthma

This publication has 29 references indexed in Scilit:

• Impact of Biologic Therapy on the Small Airways Asthma Phenotype
  Lung, 2022
• Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma
  The Journal of Allergy and Clinical Immunology: In Practice, 2022
• Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study
  The Journal of Allergy and Clinical Immunology: In Practice, 2021
• Real-life small airway outcomes in severe asthma patients receiving biologic therapies
  The Journal of Allergy and Clinical Immunology: In Practice, 2021
• Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma
  Biomedicine & Pharmacotherapy, 2020
• Mepolizumab improves small airway function in severe eosinophilic asthma
  Respiratory Medicine, 2019
• Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea
  Allergy, 2015
• Severe Asthma: Lessons Learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program
  American Journal of Respiratory and Critical Care Medicine, 2012
• Omalizumab treatment and exercise capacity in severe asthmatics – Results from a pilot study
  Respiratory Medicine, 2011
• Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease
  American Journal of Respiratory and Critical Care Medicine, 2005